Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Premium
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • PorteføljeInderes modelportefølje
  • Lær om investering
    • AnalyseskoleLær at læse og forstå aktieanalyse
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • InsidertransaktionerFølg købs- og salgsaktivitet fra virksomhedsinsidere
    • ShortsalgSe hvilke børsnoterede selskaber der har offentliggjorte korte positioner
    • Virtuel analytiker-chatStil spørgsmål og få AI-drevne investeringsindsigter med det samme
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Coegin Pharma strengthens Danish pharmacy presence - VEXIENNE® expands to Køge and southern Zealand

COEGINPressemeddelelse16.11.2026, 09.50

Coegin Pharma AB ("Coegin" or the "Company") today announces a collaboration with Køge Boholte Apotek, a pharmacy operator with four locations in Køge and southern Zealand, to introduce VEXIENNE® Hair Active X™ to its customers. The initial launch will cover two pharmacies before the end of 2026 and follows the collaboration with Taastrup Apotek announced on 13 November 2026.

With the two collaborations (Taastrup Apotek and Køge Boholte Apotek), VEXIENNE® will be introduced at five Danish pharmacies in Greater Copenhagen and on Zealand. Together with the recently announced agreement with MEDS in Sweden, they strengthen Coegin's Nordic distribution footprint and advance its strategy to scale Follicopeptide® through selected pharmacy, clinic and professional partners.

Hair Active X™ is a premium cosmetic gel serum powered by Follicopeptide®, Coegin's patented and clinically developed peptide technology for thinning hair. Deliveries to the pharmacies are planned for November, with in-store availability expected before year-end.

"Only days after announcing our collaboration with Taastrup Apotek, we are adding a second Danish pharmacy partner. The two complement each other very well: Taastrup Apotek with its strong presence in central and Greater Copenhagen, and Køge Boholte Apotek with its reach across Zealand and online. Both are led by forward-looking pharmacists, and together they give us a strong base in the Danish pharmacy channel," says Jens Eriksson, CEO of Coegin Pharma.

"Our customers ask for serious, science-based options for thinning hair, and we want to offer them a credible choice. Hair Active X™ fits well with the personal advice our staff give every day, and we look forward to offering it in our pharmacies," says Troels Ravn, pharmacy owner, Køge Boholte Apotek.

The initial introduction will take place at Køge Boholte Apotek in Køge and Rønnede Apotek on southern Zealand, with preparations under way for the planned launch before the end of 2026.

The agreement complements Coegin's existing private label partnerships and VEXIENNE® distribution model, supporting a broader and more diversified commercial footprint.

For further information, please contact:
Jens Eriksson, CEO, or Lars B. Rasmussen, CFO
Email: info@coeginpharma.com
Phone: 072-221 24 21

About Køge Boholte Apotek
Led by pharmacist Troels Ravn, Køge Boholte Apotek operates four pharmacies in Køge and southern Zealand: Køge Boholte Apotek, Ølby Apotek, Herfølge Apotek and Rønnede Apotek. The group also has a strong online presence, offering online ordering and home delivery of medicines. The pharmacies combine accessible healthcare products with qualified, personal advice on medicines and health-related products.

About Coegin Pharma
Coegin Pharma is a Swedish innovation company developing and commercializing advanced cosmetic technologies for hair and skin. Its flagship innovation, Follicopeptide®, is a patented, clinically developed peptide technology targeting hair thinning, commercialized through selected partners and the Company's VEXIENNE® brand. Coegin is also developing NPP-4, a next-generation cosmetic peptide innovation for skin tone enhancement.

With proprietary peptide technology, scalable in-house production and flexible commercial models, Coegin is building a differentiated platform for science-based cosmetic products.

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The Company is headquartered in Lund, Sweden.

For more information, including company updates and social media links, visit www.coeginpharma.com

Attached files

261116-Pressrelease.pdf